Share on LinkedInShare on LinkedIn

ARTICLE · 27 APRIL 2022

Blockbuster Blood Thinning Patent Revoked

Mr Justice Meade has revoked Bristol Myers Squibb's European patent No. EP1427415 and corresponding supplementary protection certificate that relate to the compound Apixaban (ELIQUIS) for lack of plausibility.

United KingdomIntellectual Property

Summary

Mr Justice Meade has revoked Bristol Myers Squibb's (BMS) European patent No. EP1427415 (EP'415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack of plausibility (Sandoz Limited, Teva Pharmaceuticals v Bristol-Myers Squibb Holdings [2022] EWHC 822 (Pat). Apixaban (Eliquis) is used for thromboembolic disorders and is one of BMS biggest sellers.

The invalidity action against EP'415 for "Lactam-containing compounds and derivatives thereof as factor Xa inhibitors" was brought by Teva and Sandoz, who were largely aligned in the attacks on the patent. BMS counterclaimed for infringement. BMS applied to amend to claims of EP'415 to include a requirement that the compound of the claim be either "a factor Xa inhibitor" (claim 7A) or "an effective factor Xa inhibitor" (claim 7B). Neither amendment cured the lack of plausibility so while Meade J held that claim 7A was formally allowable, he refused

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from